Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
$1.48
$1.48
$0.63
$1.51
$60.83M1.25735,654 shsN/A
BCAC
Brookline Capital Acquisition
$2.95
$0.86
$9.50
$27.74
$19.90M-0.0339,682 shs29,998 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$9.25
$12.23
$8.50
$23.00
$103.16MN/A37,647 shs1,872 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$13.25
$15.30
$5.80
$22.15
$50.58M-0.06953 shs4 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
0.00%0.00%0.00%0.00%+72.31%
BCAC
Brookline Capital Acquisition
0.00%0.00%0.00%0.00%-87.01%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-6.55%-5.71%-27.79%-14.67%+924,999,900.00%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-1.85%-6.82%-17.19%+60.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
BCAC
Brookline Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
0.00
N/AN/AN/A
BCAC
Brookline Capital Acquisition
0.00
N/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/A$3.49 per shareN/A
BCAC
Brookline Capital Acquisition
N/AN/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K3,190.87N/AN/A($0.81) per share-16.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)
BCAC
Brookline Capital Acquisition
-$480KN/A0.00N/AN/A-416.32%-4.75%N/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$4.93N/AN/AN/AN/A-2,240.92%8/12/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/AN/A
BCAC
Brookline Capital Acquisition
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/A
6.04
6.04
BCAC
Brookline Capital Acquisition
N/A
0.07
0.07
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17
CompanyEmployeesShares OutstandingFree FloatOptionable
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
25041.10 million38.89 millionNot Optionable
BCAC
Brookline Capital Acquisition
66.75 million5.45 millionNot Optionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
103.82 million2.91 millionNot Optionable

Recent News About These Companies

Harmony Biosciences Holdings
Regencell Bioscience Holdings Ltd RGC
ZIVO Bioscience Announces Uplisting to OTCQB Market
Ideaya Biosciences
Dare Bioscience Inc DARE
Zivo Bioscience Inc (ZIVO) USD0.001
Zivo Bioscience Inc ZIVO
Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

Media Sentiment Over Time

Achilles Therapeutics stock logo

Achilles Therapeutics NASDAQ:ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Brookline Capital Acquisition NASDAQ:BCAC

Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$9.25 0.00 (0.00%)
As of 07/18/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$13.25 0.00 (0.00%)
As of 07/18/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.